l-bunolol metabolites in human urine

Area of Science:

• Pharmacology
• Drug Metabolism
• Human Physiology

Background:

• Bunolol is a beta-adrenergic blocking agent.
• Understanding drug metabolism is crucial for therapeutic efficacy and safety.

Purpose of the Study:

• To identify and quantify bunolol metabolites in human urine.
• To compare human bunolol metabolism with that in animal models.

Main Methods:

• Administration of a single oral dose of radiolabeled bunolol (3H-l-bunolol) to human volunteers.
• Analysis of urine samples collected over 3 days using radiodetection methods.
• Identification of metabolites through chromatographic and spectroscopic techniques.

Main Results:

• Nine radiolabeled compounds were identified in human urine, accounting for 54.7% of the administered dose.
• Intact bunolol and its conjugates represented 19.7% of the dose.
• Dihydrobunolol was the major metabolite (28.2% of dose), retaining pharmacological activity.
• Minor acidic and hydroxylated metabolites were also identified.
• Human metabolism differed qualitatively and quantitatively from rat and dog patterns.

Conclusions:

• Bunolol undergoes extensive metabolism in humans, primarily through reduction to dihydrobunolol.
• The identified metabolites suggest both reductive and oxidative biotransformation pathways.
• Significant interspecies differences exist in bunolol metabolism.